Literature DB >> 17718861

Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC.

B Roncari1, M Pedroni, S Maffei, C Di Gregorio, G Ponti, A Scarselli, L Losi, P Benatti, L Roncucci, C De Gaetani, L Camellini, E Lucci-Cordisco, R Tricarico, M Genuardi, M Ponz de Leon.   

Abstract

A large majority of constitutional mutations in hereditary non-polyposis colorectal cancer (HNPCC) are because of the MHL 1 or MSH 2 genes. In a lower fraction of cases, another gene of the mismatch repair (MMR) machinery, MSH6, may be responsible. Families with MSH6 mutations are difficult to recognize, as microsatellite instability (MSI) may not be detectable and immunohistochemistry (IHC) may give ambiguous results. In the present study, we proposed (i) to determine the frequency of MSH6 mutations in a selected population of colorectal cancer patients obtained from a tumor registry, (ii) to assess whether IHC is a suitable tool for selecting and identifying MSH6 mutation carriers. One hundred neoplasms of the large bowel from suspected HNPCC families were analyzed for MSI (BAT 25 and BAT 26 markers) and immunohistochemical expression of the MSH6 protein. We found on 12 tumors (from different families) showing instability or lack of MSH6 expression. Among these, four potentially pathogenic MSH6 mutations were detected (del A at 2984; del TT at 3119; del AGG cod 385; and del CGT cod 1242) by direct gene sequencing. These represented 12.9% of all families with constitutional mutations of the DNA MMR genes. Thus, some 5% of all HNPCC families are featured by constitutional mutation of the MSH6 gene. This appears, however, as a minimum estimate; routine use of IHC and the study of large numbers of individuals and families with little or no evidence of Lynch syndrome might reveal that mutation of this gene account for a large fraction of HNPCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17718861     DOI: 10.1111/j.1399-0004.2007.00856.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  8 in total

Review 1.  Lynch syndrome diagnostics: decision-making process for germ-line testing.

Authors:  E Lastra; M García-González; B Llorente; C Bernuy; M J Barrio; L Pérez-Cabornero; M Durán; C García-Girón
Journal:  Clin Transl Oncol       Date:  2012-04       Impact factor: 3.405

2.  MSH6 and PMS2 mutation positive Australian Lynch syndrome families: novel mutations, cancer risk and age of diagnosis of colorectal cancer.

Authors:  Bente A Talseth-Palmer; Mary McPhillips; Claire Groombridge; Allan Spigelman; Rodney J Scott
Journal:  Hered Cancer Clin Pract       Date:  2010-05-21       Impact factor: 2.857

3.  MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria.

Authors:  Francesca Crucianelli; Rossella Tricarico; Daniela Turchetti; Greta Gorelli; Francesca Gensini; Roberta Sestini; Laura Giunti; Monica Pedroni; Maurizio Ponz de Leon; Serenella Civitelli; Maurizio Genuardi
Journal:  Epigenetics       Date:  2014-10       Impact factor: 4.528

4.  Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.

Authors:  Pei-Pei Qiao; Kai-Sai Tian; Li-Tao Han; Ben Ma; Cen-Kai Shen; Run-Yu Zhao; Yi Zhang; Wen-Jun Wei; Xiao-Ping Chen
Journal:  Endocrine       Date:  2022-04-02       Impact factor: 3.925

5.  Major contribution from recurrent alterations and MSH6 mutations in the Danish Lynch syndrome population.

Authors:  Mef Nilbert; Friedrik P Wikman; Thomas V O Hansen; Henrik B Krarup; Torben F Orntoft; Finn C Nielsen; Lone Sunde; Anne-Marie Gerdes; Dorthe Cruger; Susanne Timshel; Marie-Louise Bisgaard; Inge Bernstein; Henrik Okkels
Journal:  Fam Cancer       Date:  2008-06-20       Impact factor: 2.375

6.  First description of mutational analysis of MLH1, MSH2 and MSH6 in Algerian families with suspected Lynch syndrome.

Authors:  H Ziada-Bouchaar; K Sifi; T Filali; T Hammada; D Satta; N Abadi
Journal:  Fam Cancer       Date:  2017-01       Impact factor: 2.375

7.  Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry.

Authors:  Jinru Shia
Journal:  J Mol Diagn       Date:  2008-06-13       Impact factor: 5.568

8.  MSH6 syndrome.

Authors:  Janina Suchy; Jan Lubinski
Journal:  Hered Cancer Clin Pract       Date:  2008-06-15       Impact factor: 2.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.